Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Clear Street stuft ArriVent BioPharma-Aktie mit Kaufempfehlung ein | 2 | Investing.com Deutsch | ||
Di | Clear Street initiates ArriVent BioPharma stock with Buy rating | 3 | Investing.com | ||
Mo | Citi erhöht Kursziel für ArriVent BioPharma nach positiven Lungenkrebsdaten | 3 | Investing.com Deutsch | ||
Mo | Citi raises ArriVent BioPharma stock price target on lung cancer data | 3 | Investing.com | ||
Mo | ArriVent reports 16-month progression-free survival for lung cancer drug | 3 | Investing.com | ||
ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
Mo | ArriVent berichtet über 16-monatiges progressionsfreies Überleben bei Lungenkrebs-Medikament | 2 | Investing.com Deutsch | ||
Mo | ArriVent BioPharma, Inc.: ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study | 129 | GlobeNewswire (Europe) | 16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41%... ► Artikel lesen | |
20.06. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.06. | ArriVent BioPharma, Inc.: ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC | 2 | GlobeNewswire (USA) | ||
14.05. | ArriVent BioPharma stock target raised to $40 by H.C. Wainwright | 1 | Investing.com | ||
12.05. | ArriVent BioPharma GAAP EPS of -$1.90 | 3 | Seeking Alpha | ||
12.05. | ArriVent BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
12.05. | ArriVent Biopharma, Inc. Q1 Loss Increases, Misses Estimates | 2 | RTTNews | ||
12.05. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.04. | ArriVent BioPharma appoints new board member | 1 | Investing.com | ||
28.04. | ArriVent BioPharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
20.03. | ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside | 1 | Benzinga.com | ||
20.03. | B.Riley sets $37 target on ArriVent stock, initiates with Buy | 1 | Investing.com | ||
13.03. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
07.03. | H.C. Wainwright maintains Buy on ArriVent shares, $39 target | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |